Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

Background Immune checkpoint blockade (ICB) targeting programmed cell death protein 1 and cytotoxic T lymphocyte-associated protein 4 has achieved modest clinical activity as salvage therapy in relapsed small cell lung cancer (SCLC). We conducted this signal-finding study to assess the efficacy of I...

Full description

Bibliographic Details
Main Authors:	Shuhua Wang, Suresh Ramalingam, Sagar Lonial, Walter Curran, Edmund K Waller, Bassel Nazha, Taofeek K Owonikoko, Conor Steuer, Suchita Pakkala, Kristin Higgins, Zhengjia Chen, Gabriel Sica, Guojing Zhang, Mohammad S Hossain, Tyler Beardslee, Fadlo R Khuri
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-07-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/2/e001302.full

Similar Items

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
by: Houda Bahig, et al.
Published: (2019-01-01)

Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report
by: Syed S. Mahmood, et al.
Published: (2018-08-01)

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract
by: Michal Sarfaty, et al.
Published: (2021-02-01)

Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment
by: Sooraj John, et al.
Published: (2017-07-01)

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
by: Bassel Nazha, et al.
Published: (2020-07-01)

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.
by: Taofeek K Owonikoko, et al.
Published: (2019-01-01)

Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
by: Carol I Geppert, et al.
Published: (2020-07-01)

Tremelimumab: research and clinical development
by: Comin-Anduix B, et al.
Published: (2016-03-01)

What is the role of maintenance therapy in the treatment of non-small cell lung cancer?
by: Yixing Jiang, et al.
Published: (2010-07-01)

Remission of an Intracardiac Melanoma Metastasis after Tremelimumab Therapy
by: Sebastian Spethmann, et al.
Published: (2014-02-01)

Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data
by: Behera Madhusmita, et al.
Published: (2011-11-01)

Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract
by: Olatunji B. Alese, et al.
Published: (2015-03-01)

Natural killer T cells in advanced melanoma patients treated with tremelimumab.
by: F Javier Ibarrondo, et al.
Published: (2013-01-01)

The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
by: Cheng-Xiong Xu, et al.
Published: (2011-01-01)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
by: Jean-David Fumet, et al.
Published: (2020-08-01)

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
by: Alessandra Raimondi, et al.
Published: (2021-06-01)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
by: Siddharth Sheth, et al.
Published: (2020-07-01)

Retinal Vasculitis Secondary to Durvalumab
by: Antonio R. Andrade, et al.
Published: (2020-05-01)

c-Myc Suppression of DNA Double-strand Break Repair
by: Zhaozhong Li, et al.
Published: (2012-12-01)

Skin puckering and edema during durvalumab therapy
by: Brianna Olamiju, BA, et al.
Published: (2021-01-01)

Durvalumab in NSCLC: latest evidence and clinical potential
by: Nerea Muñoz-Unceta, et al.
Published: (2018-10-01)

Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
by: Shivani Patel, et al.
Published: (2019-12-01)

Phimosis: A rare complication of immunotherapy with durvalumab
by: Luis Gabriel Vázquez-Lavista, et al.
Published: (2020-11-01)

Durvalumab induced sarcoid‐like pulmonary lymphadenopathy
by: Emma Sanderson, et al.
Published: (2020-04-01)

In Lebanon “It Never Rains But It Pours”—How the American University of Beirut faced dangers and seized opportunities: Transforming medical education through multiple crises
by: Fadlo R. Khuri
Published: (2021-09-01)

Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
by: Paul Baverel, et al.
Published: (2019-09-01)

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
by: Ribas Antoni, et al.
Published: (2012-11-01)

Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use
by: Sean C. Dougherty, et al.
Published: (2021-06-01)

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
by: Mary H. Young, et al.
Published: (2021-08-01)

Durvalumab-Induced Diffuse Alveolar Hemorrhage: An Autopsy Case Report
by: Kensuke Kanaoka, et al.
Published: (2020-06-01)

Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
by: Yang H, et al.
Published: (2018-07-01)

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
by: Erwin H.J. Tonk, et al.
Published: (2019-08-01)

Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile.
by: Zhengjia Chen, et al.
Published: (2017-01-01)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
by: Narek Shaverdian, et al.
Published: (2020-07-01)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
by: Kageaki Taima, et al.
Published: (2020-07-01)

Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
by: Jason Cham, et al.
Published: (2021-05-01)

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
by: Martin Faehling, et al.
Published: (2021-02-01)

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
by: Shuguang Tan, et al.
Published: (2017-05-01)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
by: Kristine A. Frerichs, et al.
Published: (2021-05-01)

Durvalumab-Induced Secondary Pure Red Cell Aplasia Successfully Treated With Cyclosporin
by: Kageaki Watanabe, MD, et al.
Published: (2020-09-01)

Cannot write session to /tmp/vufind_sessions/sess_vmca2cv7bmkea01m79p5jhibr2